Neuro-Ophthalmology & Visual Neuroscience
ISSN (Print): 2572-7257 ISSN (Online): 2572-7281 Website: http://www.sciepub.com/journal/novn Editor-in-chief: Carlo Aleci
Open Access
Journal Browser
Go
Neuro-Ophthalmology & Visual Neuroscience. 2015, 1(1), 13-17
DOI: 10.12691/novn-1-1-3
Open AccessReview Article

Review on Early Neurodegenerative Changes in Diabetic Retinopathy

Amanuel Tesfay Tsegay1,

1Institute of Biomedical Sciences, College of Health Sciences, Mekelle University, Ethiopia

Pub. Date: November 27, 2014

Cite this paper:
Amanuel Tesfay Tsegay. Review on Early Neurodegenerative Changes in Diabetic Retinopathy. Neuro-Ophthalmology & Visual Neuroscience. 2015; 1(1):13-17. doi: 10.12691/novn-1-1-3

Abstract

Diabetic retinopathy (DR) is a common complication of diabetes which is the 5th primary cause of blindness globally and leading cause of blindness in the developed countries in adults at working age. This is a metabolic disorder that produces various dysfunctions in the body through Oxidative stress induced by chronic hyperglycemia. It has a direct outcome on metabolism within the neural retina, foremost to an increase in apoptosis, which in turn causes breakdown of the blood-retinal barrier. The clinical hallmark of DR includes increased vascular permeability, leading to edema and endothelial cell proliferation. Even though, there is emerging evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR, which participates in the development of microvascular abnormalities. Therefore, this review underlying mechanisms leading to neurodegeneration and the identification of the mediators between neurodegeneration and Diabetic retinopathy will be essential for the development of new therapeutic strategies.

Keywords:
Diabetic retinopathy Neurodegeneration oxidative stress blood-retinal barrier

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Leonid Poretsky (ed) (2009): Principles of Diabetes Mellitus. New York: Springer, p. 280-210.
 
[2]  Wild S, Roglic G, Greene A, et al (2004): Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 1047-1053.
 
[3]  Centers for Disease Control and Prevention (2005): Incidence of end-stage renal disease among persons with diabetes United States, 1990-2002. MMWR Morb. Mortal. Wkly. Rep. 54, 1097-1100.
 
[4]  Jeerakathil, T., Johnson, J.A., Simpson, S.H., et al. (2007): Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study2. Stroke 38, 1739-1743.
 
[5]  Peter j watkins (2003): ABC of diabetes. 2nd ed., London: BMJ Publishing Group Ltd, pp. 1-7.
 
[6]  Cockram, K.S (2002): vitamin-E deficiency. Semin. neurol., 5: 283-289.
 
[7]  Arvanitakis, Z., R.S. Wilson, J.L. Bienias, et al. (2004): Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol., 61: 661-666.
 
[8]  Boulton, A.J.M., (2005): Management of diabetic peripheral neuropathy. Clin. Diabetes, 23: 9-15.
 
[9]  Egleton, R.D., C. Campos, J. Huber, R. Brown and T. Davis (2003): Differential effects of diabetes on rat choroids plexus ion transporter expression. Diabetes, 52: 1496-1501.
 
[10]  Segal, M.B. (2000): The choroid plexuses and barriers between the blood and the cerebrospinal fluid. Cell. Mol. Neurobiol. 20: 183-196.
 
[11]  Aragno, M., R. Mastrocola, E. Brignardello, M. Catalano et al. (2002): Dehydroepiandrosterone modulates nuclear factor-kappa B activation in hippocampus of diabetic rats. Endocrinology, 143: 3250-3258.
 
[12]  Chu, J. and Ali Y. (2008): Diabetic Retinopathy. drug development research 69: 1-14.
 
[13]  American Academy of Ophthalmology (2008): American Academy of Ophthalmology Retina Panel. Preferred practice patternĀ® guidelines. Diabetic-retinopathy. San Francisco, CA. Available at: http://www.aao.org/ppp
 
[14]  Rema, M., Premkumar, S., Anitha, B. et al, (2005). Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study Eye Study I. Investigative Ophthalmology and Visual Science, 46, 2328-2333.
 
[15]  Frank, R.N. (2004): Diabetic retinopathy. New Engl. J. Med. 350, 48-58.
 
[16]  Kern, T. S, Kanwar, M.; Chan, P. S.; Kowluru, R. A. (2007): Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Investig. Ophthalmol. Vis. Sci. 48: 3805-3811.
 
[17]  Timothy, S Kern1 and Alistair J Barber. (2008): Retinal ganglion cells in diabetes. Physiol.; 586: 4401-4408.
 
[18]  Alistair, J., Erich Lieth, Sonny A. Khin David A. Antonetti, et. Al., (1998): Neural Apoptosis in the Retina during Experimental and Human Diabetes Early Onset and Effect of Insulin. J.Clin Invest.; 102: 783-791.
 
[19]  Cunha,V. J, Faria de Abreu JR, Campos AJ. (1975): Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol., 59 (11): 649-56.
 
[20]  Aiello,P., Gardner TW, King GL, et al. (1998): Diabetic retinopathy. Diabetes Care, 21 (1): 143-56.
 
[21]  Moss, S., Klein R, Klein BE. (1988): The incidence of vision loss in a diabetic population. Ophthalmology., 95 (10): 1340-1348.
 
[22]  Armulik, A., Abramsson A, Betsholtz C. (2005): Endothelial/pericyte interactions. Circ Res 97: 512-523.
 
[23]  Barber, AJ. (2003): A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 27 (2): 283-290.
 
[24]  Yankner, BA., Lu T, Loerch P. (2008): The aging brain. Annu Rev Pathol. 3: 41-66.
 
[25]  Soto, C., Estrada LD. (2008): Protein misfolding and neurodegeneration. Arch Neurol. 65: 184-189.
 
[26]  Haberland Catherine (2007): Clinical neuropathology, text and color atlas demos medical. publishing, New York. pp. 84-116.
 
[27]  Hans, P., Howard J. and Michael B. (1995): Nerve Growth Factor Prevents Both Neuroretinal Programmed Cell Death and Capillary Pathology in Experimental Diabetes; Mol. Med.; 1: 527-534.
 
[28]  Yoshinori, A., Kiyomitsu Oyanagi, Jianguo Hu and Hachiro Nakagawa. (2002): Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology; 22: 161-170.
 
[29]  Halliwell, B., Gutteridge JMC. (1989): In free radicals in Biology and Medicine, 2nd Ed,; Oxford University Press, Oxford, UK.
 
[30]  Halliwell, B., Gutteridge JMC. (1984): Oxygen toxicity, Oxygen radicals, transition metals and disease. Biochem J; 219: 1-14.
 
[31]  Kikuchi, M., Tenneti L, Lipton SA. (2000): Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. J Neurosci. 20: 5037-5044.
 
[32]  Manabe, S., Lipton SA. (2003): Divergent NMDA signals leading to proapoptotic and antiapoptotic pathways in the rat retina. Invest Ophthalmol Vis Sci.; 44: 385-392.
 
[33]  Azza, B., El-Remessy, Mohamed Al-Shabrawey, et al. (2006): Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes. Am J Pathol168: 235-244.
 
[34]  Pamela, M., Penny R., Tracy K. et al. (2004): Death of Retinal Neurons in Streptozotocin-Induced Diabetic Mice. Invest Ophthalmol Vis Sci.; 45: 3330-3336.
 
[35]  Coyle, JT., Puttfarcken P. (1993): Oxidative stress, glutamate and neurodegenerative disorders. Science; 262: 689-695.
 
[36]  Dreyer, EB., Zurakowski D, Schumer RA, Podos SM, Lipton SA. (1996): Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol; 114: 299-305.
 
[37]  Maxwell, S.R.J. (1995): Prospects for the use of antioxidant therapies, Drugs 49 (3). 345-361
 
[38]  Schulz, JB., LindenauJ., Seyfried J., and Dichgans J. (2000): Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267, 4904-4911
 
[39]  Ceriello, A., Quatraro A., Giugliano D. (1999): New insights on non-enzymatic glycosylation may lead to therapeutic approaches for pre-vention of diabetic complications, Diabetic Med. 9. 297-299.
 
[40]  Baynes, JW., Thorpe SR. (1999): Role of oxidative stress in diabetic complications. Diabetes. 48: 1-9.
 
[41]  Stitt, A.W., & Curtis T. M. (2005): Advanced glycation and retinal pathology during diabetes. Pharmacological Reports, 57:156-168
 
[42]  Anitha, B., Sampathkumar S., Balasubramanyam M., (2008): Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. Journal of Diabetes and Its Complications. 22; 261-266.
 
[43]  Balasubramanyam, M., Rema, M., & Premanand, C. (2002): Biochemical and molecular mechanisms of diabetic retinopathy. Current Science, 83, 1506-1514.
 
[44]  Barile, G.R., Pachydaki, S.I., Tari, S.R., et al (2005): The RAGE Axis in Early Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci., 46 (8), 2916-2924.
 
[45]  Maxwell, S.R.J, Thomason H., Sandler D. et al (1997): Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin dependent diabetes mellitus, Eur. J. Clin. Invest. 27; 484-490.
 
[46]  Lyons, T.J. (1991): Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med. 8; 411-419.
 
[47]  Wolff SP, Jiang ZY, Hunt JV. (1991): Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Rad Biol Med. 10: 339-352.
 
[48]  Hu, D., Jablonski KA, Henderson JA, et al. (1999): Glycemic control in diabetic American Indians. Diabetes Care. 22:1802-1807.
 
[49]  Hayashi, T., Su TP. (2007): Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca (2+) signaling and cell survival. Cell 131: 596-610.
 
[50]  Walter, L., and Hajnoczky, G. (2005): Mitochondria and endoplasmic reticulum: the lethal interorganelle cross-talk. J. Bioenerg. Biomembr. 37, 191-206.
 
[51]  Schroder, M., and Kaufman, R.J. (2005): The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789.
 
[52]  Kowluru, R. A.; Kowluru, V.; Ho, Y. S.; Xiong, Y. (2006): Over expression of mitochondrial superoxide dismutase in mice protects the retina from diabetes induced oxidative stress. Free Radic. Biol. Med. Sci. 41: 1191-1196.
 
[53]  Kowluru RA. and KanwarMamta.(2007): Effects of curcumin on retinal oxidative stress and inflammation in diabetes; Nutrition & Metabolism; 4; 1743-7075-4-8.
 
[54]  Pennathur S. and Heinecke JW. (2004): Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Frontiers in Bioscience 9, 565-574.
 
[55]  Aizu, Y., Oyanagi K, Hu J, Nakagawa H (2002): Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology, 22, 161-170.
 
[56]  Noha, A.S, Gamal M. A, Mohamed E., and Amanuel T. T(2012): Effects of Curcumin on Early Retinal Neuro-Degenerative Changes in Diabetic Albino Rats. Journal of American Science, 2012; 8 (1).
 
[57]  Park, S.H.,. Park J.-W,. Park S.-J,. Kim K.-Y,. Chung J.-W,. et al., (2003).Apoptotic death of photoreceptors in the Streptozotocin-induced diabetic rat retina; Diabetologia 46:1260-1268.
 
[58]  Martin PM., RoonP., Van Ells TK., Ganapathy V., and Smith S. (2004): Death of Retinal Neurons in Streptozotocin-Induced Diabetic Mice. Invest Ophthalmol Vis Sci.; 45: 3330-3336.
 
[59]  Zeng X-X, Ng Y-K, Ling E-A (2000): Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 17: 463-471.
 
[60]  Lieth E, Barber AJ, Xu B et al. (1998): Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes. 47: 815-820.